KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model.

Adriano Venditti, Jing-Zhou Hou, Pierre Fenaux, Brian A Jonas, Radovan Vrhovac, Pau Montesinos, Jacqueline S Garcia, David Rizzieri, Michael J Thirman, Meng Zhang, Jalaja Potluri, Catherine Miller, Mazaher Dhalla, Vinod Pullarkat

Leukemia 39(11) 2697-2707

PMID40913104
PMCIDPMC12589120
DOI10.1038/s41375-025-02730-3
发表日期2025-09-05
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Venetoclax plus azacitidine is recognized as standard of care for patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy (IC). However, some patients may still not be treated with venetoclax combinations due to frailty concerns. We evaluated efficacy and safety of venetoclax plus azacitidine vs. placebo plus azacitidine in patients with newly diagnosed AML ineligible for IC from the phase 3 VIALE-A study (NCT02993523) and the phase 1b M14-358 study (NCT02203773), stratified by two methods to potentially assess frailty. The first method was age-based (75-79, 80-84, ≥85 years; n = 303 pooled from both studies) and the second was fitness-based using the AML composite model (AML-CM), a comorbidity-based model to estimate mortality risk (Group A, B, C; n = 380, from VIALE-A). Efficacy, including composite complete remission and overall survival, were improved with venetoclax plus azacitidine vs. placebo plus azacitidine across age and AML-CM groups. Safety was generally similar between age and AML-CM groups and no new safety signals were identified. Taken together, these data suggest that patients benefit from venetoclax plus azacitidine regardless of age or degree of frailty and the combination may be considered for patients with AML who may be deemed frail. Clinical trial information NCT02993523; NCT02203773.

KM 提取结果

1 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure3 个面板

Fig. 3

Overall survival by age category. Overall survival for patients aged 75-79 years ( A ), 80-84 years ( B ), and ≥85 years ( C ). Aza azacitidine, NE not estimable, OS overall survival, Pbo placebo, Ven venetoclax.

A

Overall Survival

Fig. 3 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Overall Survival

Fig. 3 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

Overall Survival

Fig. 3 · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 2:extreme jump曲线 2:off origin start曲线 2:extreme upward reversal
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Study design and patient stratification. AML-CM acute myeloid leukemia composite model, IV intravenous, PO oral, QD once per day, SC subcutaneous.
非 KM Figure
Fig. 2Efficacy outcomes. CRc rates and MRD response rates by age category ( A ) and AML-CM group ( B ). AML-CM acute myeloid leukemia composite model, Aza azacitidine, CR complete remission, CRc complete remission + complete remission with incomplete hematologic recovery, CRi complete remission with incomplete hematologic recovery, MRD measurable residual disease, NE not estimable, Pbo placebo, Ven venetoclax.
非 KM Figure
Fig. 4Overall survival by fitness based on AML-CM score. Overall survival for patients likely to benefit from IC ( A ), less likely to benefit from IC ( B ), and likely to benefit from palliative care or a clinical trial ( C ). AML-CM acute myeloid leukemia composite model, IC intensive chemotherapy, Aza azacitidine, NR not reached, OS overall survival, Pbo placebo, Ven venetoclax.
非 KM Figure